Mounjaro and EDS: what people with Ehlers-Danlos syndromes should know

Step 1: understanding where EDS and tirzepatide's effects overlap

Ehlers-Danlos syndromes are a group of heritable connective tissue disorders affecting collagen structure. The hypermobile type (hEDS) is the most common; others include classical, vascular and kyphoscoliotic EDS. Many people with EDS carry a higher BMI, not because of lifestyle choices alone, but because reduced exercise tolerance, chronic pain, fatigue and altered gut function all affect energy balance over years. That context matters when a person with EDS arrives at a conversation about weight management.

Tirzepatide (the active ingredient in Mounjaro) works by activating both the GLP-1 and GIP receptors, slowing how quickly the stomach empties food and reducing appetite signals from the brain. This dual mechanism is why its weight-loss results in clinical trials have been striking. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the highest dose over 72 weeks. But the same gastric-slowing effect that drives weight loss can present difficulties when the gut is already prone to dysmotility, a pattern seen in a meaningful proportion of people with connective tissue disorders.

If you live with hEDS and have already noticed slow gastric emptying, bloating after meals, or nausea on an ordinary day, it is worth being specific about that history when you complete a consultation. A prescriber needs to know, not guess. You can read more about how tirzepatide works before that conversation.

Step 2: the POTS and autonomic angle

Postural orthostatic tachycardia syndrome (POTS) and other forms of dysautonomia are more prevalent among people with EDS than in the general population. Dysautonomia affects the autonomic nervous system, which among many things governs gut motility, heart rate on standing and fluid regulation. Nausea, early satiety and gastric discomfort (the most common side effects of tirzepatide) are also core features of autonomic gut dysfunction, which means these two sources of GI symptoms can be difficult to disentangle during the early weeks of treatment.

This does not rule out treatment, but it does shape how it should be managed. A prescriber familiar with your autonomic history may recommend a more gradual approach to dose increases, prioritise smaller and more frequent meals, and set clearer thresholds for when to pause or review. Hydration deserves extra attention: the NHS tirzepatide guidance notes that dehydration from prolonged nausea or vomiting can cause kidney problems, and staying hydrated is already a daily challenge for many people with POTS.

People with EDS sometimes tell us they feel their complex medical picture gets compressed into a checklist. That frustration is understandable. It is exactly why our prescribers review each consultation personally, the same-day assessment is a clinician reading your answers, not software matching keywords.

Step 3: practical considerations around injection sites and skin

Mounjaro is administered as a once-weekly subcutaneous injection into the abdomen, thigh or upper arm, rotating sites between doses. For most people this is straightforward. In EDS, skin fragility, altered healing and hypermobility at injection sites can occasionally make this worth a brief conversation with a clinician before starting.

There is no evidence that subcutaneous injections cause disproportionate harm in EDS as a category (the range of connective tissue involvement is too wide for a blanket statement) but if you have had problems with bruising, skin fragility or poor wound healing in the past, noting that history in your consultation allows the prescriber to advise accordingly. Rotating sites carefully, as the product guidance recommends, reduces localised tissue stress regardless of underlying condition.

If you are also taking medicines for blood pressure, pain or heart rate (which is common with dysautonomia) it is worth reviewing potential interactions before starting any new treatment. Our guide to Mounjaro and blood pressure medicines covers that ground in more detail. For a broader look at what a treatment programme involves, the weight-loss treatment overview is a useful starting point. And if questions around cost are on your mind, a clear breakdown of what private treatment involves is available without any obligation.

Step 4: what a prescriber will want to know before approving treatment

Because EDS is not a single condition, a prescriber assessing suitability will want a reasonably detailed picture: which type of EDS or connective tissue disorder you have been diagnosed with, whether you have a formal gastroparesis or dysmotility diagnosis, any autonomic conditions and the medicines used to manage them, and your current BMI alongside any weight-related comorbidities.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. The NICE guidance on tirzepatide (TA1026, published December 2024) covers NHS eligibility thresholds separately, but for private treatment the licensed criteria apply, assessed alongside your individual health picture. EDS itself can constitute a comorbidity that affects weight management, and if you are based in Yorkshire you may find our Mounjaro Leeds service page a helpful starting point for understanding local access. If you have questions about how treatment might interact with other aspects of your health, our pages on Mounjaro and eating disorders and whether it is safe to use sunbeds while taking Mounjaro are worth reading before your consultation.

The goal of this step is not to create barriers but to make sure, if treatment goes ahead, that it is structured in a way that works with your physiology rather than against it. If you would like that conversation, our clinical team is available every day. Speak to our prescribers through a free consultation, and bring the details that matter to you.